Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofogliflozin versus glimepiride in type 2 diabetes with NAFLD
jRCTs041180132Completed
- Sponsor
- Kowa Company, Ltd.
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of tofogliflozin in metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Kowa Company, Ltd. Primary endpoint: Improvement in histologic features of NAFLD. Started Mar 2016; status: completed.
02
Drugs
tofogliflozin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs041180132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041180132.